Correlation of High-Risk Soft Tissue Sarcoma Biomarker Expression Patterns with Outcome following Neoadjuvant Chemoradiation. (scientific article published on 28 February 2018)

Doxorubicin-induced suppression of poly(ADP-ribose) polymerase-1 (PARP-1) activity and expression and its implication for PARP inhibitors in clinical trials

Q84275102

Tissue microarray sampling strategy for prostate cancer biomarker analysis

Q39594775

Loss of function and p53 protein stabilization

Q41640250

Poly(ADP-ribose) polymerase-1 mRNA expression in human breast cancer: a meta-analysis.

Q42479746

Neoadjuvant chemotherapy and radiotherapy for large extremity soft-tissue sarcomas

Q44493058

Prognostic implications of glucose transporter protein-1 (glut-1) overexpression in bone and soft-tissue sarcomas

Q46796717

Phase II study of neoadjuvant chemotherapy and radiation therapy in the management of high-risk, high-grade, soft tissue sarcomas of the extremities and body wall: Radiation Therapy Oncology Group Trial 9514.

Q46919092

CXCR4 overexpression is associated with poor outcome in females diagnosed with stage IV non-small cell lung cancer.

Q51457342

Automated subcellular localization and quantification of protein expression in tissue microarrays.

Q52030096

Tumor oxygenation and reoxygenation during radiation therapy: their importance in predicting tumor response

Q69491072

Prognostic value of Ki-67 expression in 182 soft tissue sarcomas. Proliferation--a marker of metastasis?

Q72625560

Prognostic value of immunohistochemistry for p53 in primary soft-tissue sarcomas: a multivariate analysis of five antibodies

Q73815048

Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Sarcoma Meta-analysis Collaboration

Q73944757

Expression of hypoxia-inducible factor (HIF)-1alpha as a biomarker of outcome in soft-tissue sarcomas

Q27851402

p53-mediated senescence impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer.

Q27851827

HIF-1: mediator of physiological and pathophysiological responses to hypoxia

Q28140835

Cellular and developmental control of O2 homeostasis by hypoxia-inducible factor 1 alpha

Q28259513

Human carbonic anhydrases and carbonic anhydrase deficiencies

Q28290260

Hypoxia-inducible expression of tumor-associated carbonic anhydrases

Q28647603

A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia

Q29615437

Tissue microarrays for high-throughput molecular profiling of tumor specimens

Q29618675

The p53 gene in soft tissue sarcomas: prognostic value of DNA sequencing versus immunohistochemistry.

Q30321282

Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial

Q32073183

Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67

Q33528106

Soft tissue sarcomas and p53 mutations

Q33898768

Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules

Q34320910

A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma

Q34592760

Activation and regulation of ATM kinase activity in response to DNA double-strand breaks

Q34722727

The role of hypoxia-induced factors in tumor progression

Q35980392

Dual roles of PARP-1 promote cancer growth and progression

Q36460391

Comparison of the Ki-67 score and S-phase fraction as prognostic variables in soft-tissue sarcoma.

Q36618793

Hypoxia-driven selection of the metastatic phenotype

Q36801461

Transcriptional control of the tumor- and hypoxia-marker carbonic anhydrase 9: A one transcription factor (HIF-1) show?

Q37161440

Neoadjuvant chemoradiotherapy for patients with high-risk extremity and truncal sarcomas: a 10-year single institution retrospective study

Q37184383

Long-term results of a phase 2 study of neoadjuvant chemotherapy and radiotherapy in the management of high-risk, high-grade, soft tissue sarcomas of the extremities and body wall: Radiation Therapy Oncology Group Trial 9514.

Q37191141

Tumor cells upregulate normoxic HIF-1α in response to doxorubicin

Q37238828

Hypoxia-dependent modification of collagen networks promotes sarcoma metastasis.

Q37294778

Multiple roles of the ERCC1-XPF endonuclease in DNA repair and resistance to anticancer drugs

Q37799971

ERCC5/XPG, ERCC1, and BRCA1 gene status and clinical benefit of trabectedin in patients with soft tissue sarcoma

Q38337608

Topoisomerase II-alpha protein expression and histological response following doxorubicin-based induction chemotherapy predict survival of locally advanced soft tissues sarcomas

Q38411100

Poly(adenosine diphosphate-ribose) polymerase expression in serous ovarian carcinoma: correlation with p53, MIB-1, and outcome

Q38433139

Carbonic anhydrase IX as a marker for poor prognosis in soft tissue sarcoma

Q38447056

HIF-1 Alpha Regulates the Response of Primary Sarcomas to Radiation Therapy through a Cell Autonomous Mechanism.

Q38874972

P275

Creative Commons Attribution 4.0 International

Q20007257

P6216

copyrighted